Green Synthesis of Silver Nanoparticles Loaded with Doxorubicin in Polylactide Nanoparticles for Effective Cancer Therapy

IF 2.7 4区化学 Q2 CHEMISTRY, INORGANIC & NUCLEAR Journal of Cluster Science Pub Date : 2024-09-21 DOI:10.1007/s10876-024-02700-2

Mohyeddin Assali, Anhar Mlitat, Abrar Yacoub, Anagheem Hasson, Ahmed Mousa

{"title":"Green Synthesis of Silver Nanoparticles Loaded with Doxorubicin in Polylactide Nanoparticles for Effective Cancer Therapy","authors":"Mohyeddin Assali, Anhar Mlitat, Abrar Yacoub, Anagheem Hasson, Ahmed Mousa","doi":"10.1007/s10876-024-02700-2","DOIUrl":null,"url":null,"abstract":"<div><p>Silver nanoparticles (AgNPs) are increasingly recognized as vital nanomaterials in biomedical applications due to their diverse pharmacological properties, including antimicrobial and anti-neoplastic effects, particularly when derived from herbal sources. This study aims to synthesize AgNPs employing a sustainable approach aligned with the principles of the sustainable development goals. The synthesized AgNPs are incorporated with doxorubicin (DOX) and encapsulated within polylactide nanoparticles to enhance their anticancer potency. AgNPs are prepared via the reduction of silver ions using rutin as a reducing agent, with the reaction progress monitored via ultraviolet-visible spectroscopy (UV-vis). Subsequently, the AgNPs are encapsulated into poly(D, L-lactic acid) (PDLLA) nanoparticles alongside doxorubicin. The developed nanoparticles have shown a diameter size of 233 nm with a zeta potential of -21.47 mV. Moreover, the in vitro release profile of the DOX showed a sustained release kinetics over 30 h. Evaluation of the AgNP-DOX-loaded PDLLA nanoparticles reveals enhanced anticancer activity against HeLa and HepG2 cancer cells, highlighting the synergistic efficacy of the combined therapy. These findings underscore the potential of AgNPs-based formulations as promising candidates for advanced cancer therapeutics.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":618,"journal":{"name":"Journal of Cluster Science","volume":"35 8","pages":"2813 - 2821"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cluster Science","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s10876-024-02700-2","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}

引用次数: 0

Abstract

Silver nanoparticles (AgNPs) are increasingly recognized as vital nanomaterials in biomedical applications due to their diverse pharmacological properties, including antimicrobial and anti-neoplastic effects, particularly when derived from herbal sources. This study aims to synthesize AgNPs employing a sustainable approach aligned with the principles of the sustainable development goals. The synthesized AgNPs are incorporated with doxorubicin (DOX) and encapsulated within polylactide nanoparticles to enhance their anticancer potency. AgNPs are prepared via the reduction of silver ions using rutin as a reducing agent, with the reaction progress monitored via ultraviolet-visible spectroscopy (UV-vis). Subsequently, the AgNPs are encapsulated into poly(D, L-lactic acid) (PDLLA) nanoparticles alongside doxorubicin. The developed nanoparticles have shown a diameter size of 233 nm with a zeta potential of -21.47 mV. Moreover, the in vitro release profile of the DOX showed a sustained release kinetics over 30 h. Evaluation of the AgNP-DOX-loaded PDLLA nanoparticles reveals enhanced anticancer activity against HeLa and HepG2 cancer cells, highlighting the synergistic efficacy of the combined therapy. These findings underscore the potential of AgNPs-based formulations as promising candidates for advanced cancer therapeutics.

Graphical Abstract

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在聚乳酸纳米粒子中负载多柔比星的银纳米粒子的绿色合成，用于有效治疗癌症

银纳米粒子（AgNPs）具有多种药理特性，包括抗菌和抗肿瘤作用，尤其是从草药中提取的银纳米粒子，因此越来越被认为是生物医学应用中的重要纳米材料。本研究旨在采用符合可持续发展目标原则的可持续方法合成 AgNPs。合成的 AgNPs 与多柔比星（DOX）结合并封装在聚乳酸纳米颗粒中，以增强其抗癌效力。AgNPs 是以芦丁作为还原剂，通过还原银离子来制备的，反应过程通过紫外可见光谱（UV-vis）进行监控。随后，将 AgNPs 与多柔比星一起封装到聚（D，L-乳酸）（PDLLA）纳米粒子中。所开发的纳米颗粒直径为 233 nm，zeta 电位为 -21.47 mV。对 AgNP-DOX 负载 PDLLA 纳米颗粒的评估显示，其对 HeLa 和 HepG2 癌细胞的抗癌活性得到了增强，凸显了联合疗法的协同功效。这些发现凸显了基于AgNPs的制剂作为先进癌症疗法候选药物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Cluster Science 化学-无机化学与核化学

CiteScore

6.70

自引率

0.00%

发文量

166

审稿时长

3 months

期刊介绍： The journal publishes the following types of papers: (a) original and important research; (b) authoritative comprehensive reviews or short overviews of topics of current interest; (c) brief but urgent communications on new significant research; and (d) commentaries intended to foster the exchange of innovative or provocative ideas, and to encourage dialogue, amongst researchers working in different cluster disciplines.